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An ertapenem-resistant Escherichia coli isolate was
recovered from peritoneal fluid in a patient who had been
treated with imipenem/cilastatin for 10 days. Ertapenem
resistance may be explained by a defect in the outer mem-
brane protein and production of extended-spectrum 
β-lactamase CTX-M-2.
O
f all β-lactam antimicrobial drugs, carbapenems
(imipenem, meropenem, and ertapenem) have the
most consistent activity against Enterobacteriaceae.
Activity is retained against most isolates that produce
high-level AmpC β-lactamases (cephalosporinases) and
clavulanic-acid–inhibited extended-spectrum β-lactamases
(ESBL) (1). However, a few carbapenem-resistant enter-
obacterial isolates have been reported; resistance may be
caused by production of carbapenemases (2) or by com-
bined mechanisms of an outer membrane permeability
defect and extended-spectrum β-lactamases or
cephalosporinase (3–6). Spread of CTX-M type ESBLs,
especially in Escherichia coli, may provide a favorable
background for selection of carbapenem resistance.
Resistance to the recently introduced ertapenem has not
been reported in E. coli associated with a CTX-M-type
enzyme. We describe the clinical and microbiologic fea-
tures associated with an ertapenem-resistant E. coli isolate
that had reduced susceptibility to imipenem after in vivo
treatment with imipenem/cilastatin and provide a detailed
molecular analysis of the antimicrobial drug resistance
mechanisms.
The Study
E. coli CO strain was recovered from a 50-year-old
immunocompromised woman who was hospitalized for a
combined liver and heart transplant. She had a history of
cardiac failure, hepatitis C virus–related liver cirrhosis,
and chronic renal insufficiency. After surgery, septic shock
developed related to perforation of the colon. The patient
received a full dose of imipenem/cilastatin (2 g/day), a
reduced dose of vancomycin (400 mg/day), gentamicin
(100 mg/day for 2 days), and fluconazole (100 mg/day).
Ten days later, peritoneal lavage and surgery to remove
diseased colonic tissue were performed, but the patient
died 2 days after surgery. Culture of the peritoneal fluid
yielded an ertapenem-resistant E. coli CO strain. 
Disk diffusion susceptibility testing with antimicro-
bial drug–containing disks (Sanofi Diagnostics Pasteur,
Marnes-la-Coquette, France) (7) was performed with and
without cloxacillin (250 mg/L), which is a β-lactam mole-
cule that inhibits in vitro cephalosporinase activity (5).
MICs were determined by an agar dilution technique and
interpreted according to Clinical and Laboratory Standards
Institute guidelines (7). The E. coli CO strain was resistant
to extended-spectrum cephalosporins, cefoxitin, and mox-
alactam. In addition, it was intermediately susceptible to
imipenem and meropenem (MIC 8 mg/L each) and was
resistant to ertapenem (MIC >256 mg/L) (Table). The E.
coli CO strain was also resistant to gentamicin, kanamycin,
chloramphenicol, tetracycline, and trimethoprim-sul-
famethoxazole; intermediately susceptible to nalidixic acid
and tobramycin; and remained susceptible to amikacin,
netilmicin, ofloxacin, and ciprofloxacin. Antimicrobial
drug susceptibility testing on cloxacillin-containing plates
indicated absence of consequential cephalosporinase activ-
ity. However, the ceftazidime/clavulanic acid synergy test
result was slightly positive. A β-lactamase extract from a
culture of E. coli CO subjected to isoelectric focusing
analysis showed 3 β-lactamase activities with pI values of
5.4, 6.1, and 7.9 (8). This extract did not hydrolyze car-
bapenems according to spectrophotometer measurements
(8). Conjugation experiments that used an azide-resistant
E. coli J53 strain as recipient strain (5), followed by selec-
tion on Mueller-Hinton agar plates containing 100 mg/L
sodium azide and 100 mg/L amoxicillin or 2 mg/L of cefo-
taxime, yielded transconjugants. Two conjugative plas-
mids (pCO-1, 160 kb; pCO-2, 150 kb) were extracted from
those transconjugants by the Kieser technique (5). They
conferred resistance to amoxicillin and ticarcillin, whereas
pCO-1 conferred additional resistance to extended-spec-
trum cephalosporins (Table). These transconjugants were
fully susceptible to carbapenems. Standard PCR condi-
tions were used to amplify several β-lactamase genes cod-
ing for carbapenemases (blaKPC,  blaNMC-A); extended-
spectrum β-lactamases including blaTEM, blaSHV, blaCTX-M,
blaVEB, blaPER; and oxacillinases (OXA-1, OXA-2, OXA-
10, OXA-21, and OXA-48) (2,9). PCR amplification and
sequencing identified an extended-spectrum β-lactamase
blaCTX-M-2 gene located on plasmid pCO-1, whereas a
blaTEM-1 gene that coded for narrow-spectrum penicillinase
and a blaOXA-10 gene that coded for oxacillinase were both
located on a 150-kb plasmid pCO-2. The surrounding
regions of the blaCTX-M-2 gene corresponded to those of a
sul1-type class 1 integron. This gene was bracketed by a
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class 1 integron and was not associated with a 59-bp ele-
ment. The common region open reading frame (ORF) 513
was found upstream of the blaCTX-M-2 gene (data not
shown) (10).
The outer membrane protein (OMP) profiles of E. coli
isolates were extracted and analyzed by using sodium
dodecyl sulfate–polyacrylamide gel electrophoresis, as
described (4,5,11,12) and compared with profiles of E. coli
control strains expressing porins OmpC or OmpF (13).
The OMP profiles of E. coli CO showed expression of
OmpA and OmpF and no expression of OmpC (Figure).
Using whole-cell DNA of E. coli CO as a template and
primers EcOmpFA (5′-CAGGTACTGCAAACGCTGC-
3′) and EcOmpFB (5′-GTCAACATAGGTGGAC ATG-3′)
that anneal at the ends of the ompF gene of E. coli (5), we
obtained a 953-bp internal fragment of the ompF gene
(data not shown). Sequencing identified a wild-type ompF
gene. When primers EcOmpCA (5′-GTTAAAGTACT
GTCCCTCCTG-3′) and EcOmpCB (5′-GAACTG
GTAAACCAGACCCAG-3′) were used, no amplification
was obtained for E. coli CO, whereas a 1,086-bp internal
fragment of the ompC gene of the  E. coli control strain
expressing OmpC (10) and of 3 wild-type E. coli strains
was amplified (data not shown). Thus, the ompC gene was
either disrupted or not present, which explains lack of
expression of this protein and might contribute substantial-
ly to ertapenem resistance of E. coli CO.
Conclusions
Ertapenem resistance has been reported in Klebsiella
pneumoniae–producing CTX-M–type ESBLs that have a
permeability defect (3,4,14). We report here the first
ertapenem-resistant E. coli clinical isolate that produced a
CTX-M-type ESBL and that was deficient in porin OmpC.
This finding may be clinically relevant because ertapenem
is approved for treatment of peritonitis, abdominal infec-
tion, and complicated skin and soft tissue infections in
DISPATCHES
316 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 2, February 2007
Figure. Outer membrane protein (OMP) profiles of Escherichia coli
strains. OMP content was determined by using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Lane 1 corresponds to
E. coli CO clinical isolate; lane 2, E. coli JF 568 strain expressing
OmpC; lane 3, E. coli JF 701 strain lacking OmpC (9). The molec-
ular mass marker (M) and corresponding sizes (in kilodaltons) are
indicated on the left. Horizontal arrows on the right indicate posi-
tions of the OMPs OmpF, OmpC, and OmpA.patients with diabetes and because E. coli is the main
species isolated in human infections and the main enter-
obacterial species that expresses these emerging extended-
spectrum  β-lactamases CTX-M (15). That an
imipenem/cilastatin–containing regimen was likely able to
select for ertapenem resistance is cause for concern.
Moreover, even if the strain is not resistant to imipenem
and meropenem, it is no longer totally susceptible.
Susceptibility patterns of this E. coli CO strain, although
resistant to ertapenem, are also highly resistant to extend-
ed-spectrum cephalosporins, thereby demonstrating an
ESBL phenotype. This information may help with future
identification of those multidrug CTX-M (+) resistance
isolates for which the best treatment remains carbapenems.
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